Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Obstetrics and Gynaecology
  • Obstetrics and Gynaecology News
  • Minimally Invasive...

Minimally Invasive Surgery in Advanced epithelial ovarian cancer: Study evaluates Outcomes in Face of Complications

Written By : Dr Pooja N. |Written By : Dr. Kamal Kant Kohli Published On 2025-01-05T20:30:11+05:30  |  Updated On 6 Jan 2025 12:08 PM IST
Minimally Invasive Surgery in Advanced epithelial ovarian cancer: Study evaluates Outcomes in Face of Complications
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

Cytoreductive surgery, whether performed as the initial treatment or following neoadjuvant chemotherapy (NACT) for advanced epithelial ovarian cancer (EOC), fallopian tube carcinoma, and primary peritoneal cancer, poses significant risks of complications. These complications can delay the timely delivery of chemotherapy, extend hospital stays and lead to readmissions, ultimately affecting survival rates negatively. Recent study evaluates the feasibility of conducting a randomized clinical trial (RCT) to compare the efficacy of minimally invasive surgery (MIS) against traditional laparotomy for patients with advanced-stage epithelial ovarian cancer (EOC) who have responded to neoadjuvant chemotherapy (NACT). The research is part of the Laparoscopic Cytoreduction After Neoadjuvant Chemotherapy (LANCE) trial, which focuses on patients with stage IIIC or IV EOC, specifically those showing a complete or partial response to NACT.

Pilot Phase Details

The pilot phase, initiated in September 2020 and concluding with the enrollment of the 100th patient in February 2023, included participants from 11 academic cancer centers across North America and Europe. Inclusion criteria encompassed adult patients exhibiting elevated cancer antigen 125 (CA-125) levels and a partial or complete radiologic response after 3-4 cycles of NACT. Patients were randomly assigned to either an MIS arm, involving laparoscopic or robotic surgery, or a laparotomy control arm. Outcomes were assessed primarily on feasibility metrics such as patient accrual rates, conversion rates from MIS to laparotomy, and rates of complete gross resection. The study successfully enrolled 100 patients (median age 63 years), with 49 in the MIS group and 51 in the laparotomy group. The results indicated a patient accrual rate of 5.9 patients per month, surpassing the predefined threshold. Conversion from MIS to laparotomy occurred in 12.5% of the MIS group, which met the pre-established criterion of being below 25%. Overall, complete gross resection was achieved in 88% of the MIS group and 83% of the laparotomy group, reflecting a small absolute difference that was well within acceptable limits.

Secondary Outcomes

Secondary outcomes reported that patients in the MIS arm experienced significantly shorter postoperative hospital stays (median of 1 day vs. 4 days for laparotomy) and lower estimated blood loss. However, there were more postoperative complications in the laparotomy group (26% compared to 8% in the MIS group), suggesting a possible advantage of MIS in reducing complications. No substantial differences in overall health-related quality of life were noted, aside from marginally higher social functioning in the MIS group. These findings provide preliminary evidence supporting the feasibility of the LANCE trial and suggest that MIS may be associated with fewer complications and shorter recovery times compared to laparotomy in the surgical management of advanced EOC. Further research in the form of a full-scale RCT is warranted to establish the oncological effectiveness of MIS.

Key Points

- The study assesses the feasibility of a randomized clinical trial comparing minimally invasive surgery (MIS) with traditional laparotomy for patients with advanced-stage epithelial ovarian cancer (EOC) who responded to neoadjuvant chemotherapy (NACT), as part of the LANCE trial.

- The pilot phase, running from September 2020 to February 2023, included 100 patients from 11 academic cancer centers in North America and Europe, with a median age of 63 years. Patients met specific inclusion criteria, including elevated CA-125 levels and radiologic responses to NACT.

- Participants were randomly allocated to either the MIS group, which involved laparoscopic or robotic surgery, or the laparotomy control group. Key feasibility metrics assessed were patient accrual rates, conversion rates from MIS to laparotomy, and rates of complete gross resection.

- The trial successfully enrolled 100 patients, achieving a patient accrual rate of 5.9 per month and maintaining a conversion rate from MIS to laparotomy at 12.5%, below the threshold of 25%. Complete gross resection was accomplished in 88% of the MIS cohort and 83% of the laparotomy cohort.

- Secondary outcomes indicated that the MIS arm had significantly shorter postoperative hospital stays (median 1 day) and lower estimated blood loss compared to the laparotomy group (median 4 days), along with fewer postoperative complications (8% in MIS vs. 26% in laparotomy).

- Overall health-related quality of life did not show substantial differences between groups, though the MIS group reported marginally better social functioning. These preliminary findings support the feasibility of the LANCE trial and suggest potential advantages of MIS in terms of lower complications and quicker recovery, warranting further investigation in a full-scale RCT.

Reference –

J. Rauh-Hain et al. (2024). Laparoscopic Cytoreduction After Neoadjuvant Chemotherapy In High-Grade Epithelial Ovarian Cancer. *JAMA Network Open*, 7. https://doi.org/10.1001/jamanetworkopen.2024.46325

Minimally invasive surgery (MIS)Advanced epithelial ovarian cancer (EOC)Randomized clinical trial (RCT)
Dr Pooja N.
Dr Pooja N.

    She has done her MBBS and later DGO. She is working as a private practitioner.

    Dr. Kamal Kant Kohli
    Dr. Kamal Kant Kohli

    Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

    Show Full Article
    Next Story

    Editorial

    Azmarda Outperforms Generic Sacubitril/Valsartan in HFrEF Management, says new study

    Azmarda Outperforms Generic Sacubitril/Valsartan in HFrEF Management, says new study

    First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

    First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

    Re-visiting the Role of Pneumococcal Vaccination in Patients with Cardiovascular Diseases

    Re-visiting the Role of Pneumococcal Vaccination in Patients with Cardiovascular Diseases

    Prediabetes and the Mind: Unraveling Cognitive and Mental Health Risks

    Prediabetes and the Mind: Unraveling Cognitive and Mental Health Risks

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer - Dr Aditya Murali

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer...

    View All

    Journal Club Today

    Universal Heart Health Advice Ignores Realities in Low-Income Countries: Study Finds

    Universal Heart Health Advice Ignores Realities in Low-Income Countries: Study Finds

    View All

    Health News Today

    Health Bulletin 24/May/2025

    Health Bulletin 24/May/2025

    View All
    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok